Starpharma kicks off phase III VivaGel trials
22 March, 2012 by Dylan Bushell-EmblingMelbourne's Starpharma Holdings (ASX:SPL) has commenced two phase III trials of VivaGel as a BV treatment, the results of which will be pivotal to its New Drug Application with the FDA.
AusMedtech registrations launched
22 March, 2012 by AusBiotechEarly bird registration is now available for the 2012 AusMedtech national conference to be held in Sydney, Australia’s medical technology hub.
Intellectual property reform passes House of Reps
21 March, 2012 by Tim DeanThe Raising the Bar Bill that reforms Australia’s intellectual property laws has passed both houses of parliament and will soon be signed into law.
HealthLinx ready for South Korean OvPlex trial
21 March, 2012 by Dylan Bushell-EmblingMelbourne's HealthLinx (ASX:HTX) has taken another step towards gaining regulatory approval to sell OvPlex in South Korea, by laying the groundwork for a trial.
Biota to boost Melbourne facilities
21 March, 2012 by Dylan Bushell-EmblingBiota (ASX:BTA) will expand its facilities in Melbourne to allow it to fulfil a $220m contract for the advanced development of a influenza antiviral in the US.
Patrys publishes PAT-SM6 trial results
20 March, 2012 by Dylan Bushell-EmblingMelbourne's Patrys Limited (ASX:PAB) has published the results of a safety and tolerability trial of anti-cancer antibody PAT-SM6.
Launch of the CEO survey at April member-only briefings
20 March, 2012 by AusBiotechAusBiotech’s 2012 CEO Biotechnology Industry Position Survey will be launched by AusBiotech’s CEO, Dr Anna Lavelle, at the member-only briefings in April.
Pharmaxis to get PBS tick for Bronchitol
20 March, 2012 by Tim DeanPharmaxis’ cystic fibrosis treatment Bronchitol is slated to be listed on the Pharmaceutical Benefits Scheme for reimbursement.
Vale Andrew Baker
20 March, 2012 by Staff WritersBiotechnology and pharmaceutical industry veteran and GBS Ventures partner, Dr Andrew Baker, died on Sunday March 18 from cancer.
REVA Medical gets major new investors
20 March, 2012 by Dylan Bushell-EmblingA group of buyers including Elliott Management have purchased $23m worth of CDIs and shares in ASX-listed US medical device company REVA Medical (ASX:RVA).
QRxPharma signs licensing deal with Actavis
20 March, 2012 by Dylan Bushell-EmblingQRxPharma (ASX:QRX) has closed a deal to license its dual-opioid pain product, MoxDuo IR, to pharmaceutical company Actavis.
Bioniche secures $19m finance facility
19 March, 2012 by Dylan Bushell-EmblingDual-listed biotech Bioniche (ASX:BNC) has negotiated to receive a $19m, non-dilutive finance facility from the USA's Capital Royalty.
LBT Innovations applies for APAS patents
16 March, 2012 by Dylan Bushell-EmblingLBT Innovations (ASX:LBT) has filed applications for international patents for its second invention, the Automated Plate Assessment System (APAS).
Pharmaxis close to EU approval for Bronchitol
16 March, 2012 by Dylan Bushell-EmblingPharmaxis (ASX:PXS) has been notified that it should soon receive approval for its marketing application to sell its Bronchitol cystic fibrosis treatment in the EU.
Prima BioMed gets TGA nod to manufacture CVac
15 March, 2012 by Dylan Bushell-EmblingThe TGA has granted manufacturing approval for Prima BioMed (ASX:PRR) to produce its CVac ovarian cancer vaccine in Australia, for use in a major clinical trial.
